In the brain, melatonin is an important physiological antioxidant due to its lipid and water-soluble properties ability to freely cross the blood-brain barrier
Expect formal US biosimilar filings starting in 2032 to 2034, with tentative approvals lining up for launches in 2036 to 2037 when key patents expire
Next, a detailed historical chronology is presented, covering each major GLP-1-based drug: how it was developed, trial results, and its clinical role
Explore our patient resources below for guidance, education, and supportso you always feel informed and confident in your care
Since satiety and reduced appetite are key contributors to weight loss, managing these symptoms while maintaining the therapeutic efficacy of GLP-1RAs should be carefully balanced
2024;14(6):e086603